Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.50
+0.15 (1.12%)
Dec 20, 2024, 4:00 PM EST - Market closed
Contineum Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | 50 | - | - |
| Gross Profit | - | 50 | - | - |
| Selling, General & Admin | 11.1 | 7.26 | 6.63 | 6.29 |
| Research & Development | 32.42 | 26.67 | 16.09 | 22.36 |
| Operating Expenses | 43.52 | 33.92 | 22.72 | 28.65 |
| Operating Income | -43.52 | 16.08 | -22.72 | -28.65 |
| Interest Expense | - | -0.21 | -0.39 | -0.33 |
| Interest & Investment Income | 8.17 | 4.61 | 0.76 | 0.08 |
| Other Non Operating Income (Expenses) | -0.27 | 2.7 | -1.91 | -0.1 |
| Pretax Income | -35.62 | 23.17 | -24.25 | -29 |
| Income Tax Expense | -0.16 | 0.45 | - | - |
| Net Income | -35.46 | 22.72 | -24.25 | -29 |
| Preferred Dividends & Other Adjustments | -6.58 | 19.57 | - | - |
| Net Income to Common | -28.89 | 3.15 | -24.25 | -29 |
| Shares Outstanding (Basic) | 13 | 2 | 2 | 2 |
| Shares Outstanding (Diluted) | 13 | 3 | 2 | 2 |
| Shares Change (YoY) | 488.88% | 51.38% | 6.35% | - |
| EPS (Basic) | -2.14 | 1.36 | -10.81 | -13.75 |
| EPS (Diluted) | -2.14 | 0.08 | -10.81 | -13.77 |
| Free Cash Flow | -34 | 18.94 | -20.24 | -26.43 |
| Free Cash Flow Per Share | -2.52 | 5.58 | -9.02 | -12.53 |
| Gross Margin | - | 100.00% | - | - |
| Operating Margin | - | 32.15% | - | - |
| Profit Margin | - | 6.29% | - | - |
| Free Cash Flow Margin | - | 37.87% | - | - |
| EBITDA | -43.3 | 16.27 | -22.39 | -28.32 |
| EBITDA Margin | - | 32.54% | - | - |
| D&A For EBITDA | 0.22 | 0.2 | 0.33 | 0.33 |
| EBIT | -43.52 | 16.08 | -22.72 | -28.65 |
| EBIT Margin | - | 32.15% | - | - |
| Effective Tax Rate | - | 1.94% | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.